APIMEDS PHARMACEUTICALS US I (APUS) Forecast, Price Target & Analyst Ratings

NYSEARCA:APUSUS03771D1028

Current stock price

1.62 USD
+0.21 (+14.89%)
At close:
1.611 USD
-0.01 (-0.56%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for APIMEDS PHARMACEUTICALS US I (APUS).

Forecast Snapshot

Consensus Price Target

Price Target
N/A
N/A

Next Earnings Forecast

Earnings Estimate
Release Date
N/A

ChartMill Buy Consensus

Rating
%
Weighted Analyst Rating Score

Price Target Details & History

Consensus Price Target and Range

Mean target
N/A
Upside
N/A
From current price of $1.62 to mean target of N/A, Based on analyst forecasts
Low
N/A
Median
N/A
High
N/A

Price Target Revisions

1 Month
N/A
3 Months
N/A

Price Target Summary

Analyst Ratings & History

Current Analyst Ratings

Analyst Ratings History

Analyst Ratings Consensus

ChartMill Buy Consensus
%

Recent Upgrades & Downgrades

Next Earnings Forecast Details

Next Earnings Details

Release Date
N/A

Next Earnings Revisions

Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A

Next Earnings Summary

Full Analyst Estimates

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2022 2023 2024
Revenue
YoY % growth
APUS revenue by date.APUS revenue by date.
EBITDA
YoY % growth
APUS ebitda by date.APUS ebitda by date.
N/AN/AN/A
EBIT
YoY % growth
APUS ebit by date.APUS ebit by date.
-639.5K-747.4K
-16.87%
-1.275M
-70.60%
Operating Margin
APUS operating margin by date.APUS operating margin by date.
N/AN/AN/A
EPS
YoY % growth
APUS eps by date.APUS eps by date.
N/AN/AN/A

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

EPS
Q2Q % growth
Revenue
Q2Q % growth
EBITDA
Q2Q % growth
EBIT
Q2Q % growth

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
N/A
EPS Next 5 Year
N/A

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A

APIMEDS PHARMACEUTICALS US I / APUS Forecast FAQ